Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from atopy patch testing in atopic dermatitis.

Karin Kerschenlohr1, Ulf Darsow, Walter H C Burgdorf

  • 1Laboratory of Immunodermatology, Department of Dermatology, Ludwig-Maximilian-University, Munich, Germany.

Current Allergy and Asthma Reports
|June 4, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry.

The Journal of investigative dermatology·2026
Same author

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Allergologie select·2026
Same author

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Dermatology and therapy·2026
Same author

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Acta dermato-venereologica·2026
Same author

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

The Journal of dermatological treatment·2026
Same author

Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis.

American journal of clinical dermatology·2026

The atopy patch test (APT) offers a standardized method for diagnosing atopic eczema (AE) by applying allergens to the skin. This test helps identify specific triggers, even when IgE levels are normal.

Area of Science:

  • Dermatology
  • Allergology
  • Immunology

Background:

  • Atopic eczema (AE) exacerbations are often triggered by protein allergens.
  • Accurate diagnosis is crucial for effective allergen avoidance strategies.
  • Existing tests like skin prick tests and serum IgE tests have limitations.

Purpose of the Study:

  • To present a standardized atopy patch test (APT) technique developed by the European Task Force on Atopic Dermatitis (ETFAD).
  • To highlight the APT's role in diagnosing AE by targeting cellular mechanisms.
  • To emphasize the APT's utility in identifying relevant allergen sensitization, even in the absence of specific IgE.

Main Methods:

  • Standardized epicutaneous application of intact protein allergens in a patch test.
  • Use of purified allergen preparations in petrolatum within Finn chambers on Scanpor tape.

Related Experiment Videos

  • Application to non-irritated, non-abraded, or tape-stripped skin on the upper back.
  • Evaluation of eczematous skin lesions at 48 and 72 hours using ETFAD criteria.

    • Main Results:

    • The APT targets the cellular component of AE, complementing other diagnostic methods.
    • The standardized technique aims to improve sensitivity, specificity, and reproducibility.
    • Studies have focused on objectifying the APT's diagnostic accuracy.

    Conclusions:

    • The standardized APT provides a valuable tool for diagnosing AE triggers.
    • It can detect sensitization missed by IgE-based tests.
    • The APT aids in refining allergen avoidance recommendations for AE patients.